Up­dat­ed: Ab­b­Vie leaves some on­col­o­gy pro­grams out of 2023 pipeline high­lights

In an in­vestor up­date Thurs­day morn­ing, Ab­b­Vie left eight pro­grams out of its pipeline high­lights it shared with in­vestors, as com­pared to what ex­ists on the R&D page of its web­site, last re­freshed in De­cem­ber.

A Phase III study of Rin­voq in Takaya­su ar­teri­tis, a rare group of dis­or­ders in which blood ves­sels be­come in­flamed, was not in­clud­ed. The JAK in­hibitor is ap­proved for in­di­ca­tions like rheuma­toid arthri­tis and car­ries with it a black box warn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER